AI · SEMICONDUCTOR · FACT CHECK
SKD WIRETrue
The U.S. Food and Drug Administration (FDA) has opened a public comment period on how to regulate medical devices that incorporate generative AI, collecting stakeholder input through the 19th. The move marks a step toward establishing a regulatory framework for AI-powered medical products whose capabilities and risks differ from conventional devices.
Generative AI-based medical devices present regulatory challenges that existing approval pathways were not designed to address. Unlike traditional software as a medical device, generative AI systems can produce variable outputs and evolve after deployment, raising questions about how the FDA should evaluate safety and effectiveness both before market entry and during the product life cycle.
The FDA is using the comment period to gather perspectives from developers, health care providers, patients and other stakeholders on these questions. Feedback submitted by the deadline will inform the agency's thinking as it considers how oversight of generative AI medical devices should be structured.
Stakeholders have until the 19th of this month to submit their input to the FDA. The comment window gives companies developing AI-based medical technologies an opportunity to weigh in on proposals that could shape future requirements for clinical validation, transparency and post-market monitoring.
The FDA has been among the most active regulators worldwide on AI in medical products, and the current discussion on generative AI extends that work into technologies such as large language models now being integrated into clinical tools.
The FDA's public comment process on generative AI medical device regulation, open through the 19th, is True.
